Share
University Hospital Bristol has presented groundbreaking results at the British Radiation Safety Society (BRSS) conference, showcasing the use of TrueInvivo’s® DOSEmapper™ technology in gamma knife radiosurgery. The innovative micro silica bead TLD system provided precise dose measurements, ensuring accurate delivery and improved patient safety in stereotactic radiosurgery.
This marks a significant advancement in dosimetry, highlighting the potential of DOSEmapper™ to enhance radiation safety and accuracy in complex treatments.
Related Posts
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,
TRUEinvivo's DOSEmapper™ technology receives enthusiastic feedback from industry leaders at ESTRO37 conference.
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021
